United Kingdom Immunotherapy Market to be Dominated by Monoclonal Antibodies Through 2028
Increasing adoption of target therapy
and expanding adoption of biosimilar drugs are expected to drive the United
Kingdom Immunotherapy Market in the forecast period 2024-2028.
According
to TechSci Research report, “United Kingdom Immunotherapy Market – By Region, Competition Forecast and
Opportunities, 2018-2028F,”
the United Kingdom Immunotherapy Market
is anticipated to grow at a significant rate in the forecast period, 2024-2028.
The Immunotherapy market in United
Kingdom is witnessing significant growth, driven by the increasing prevalence
of cancer and adoption of biosimilar drugs. Biosimilar drugs are highly similar
copies of biologic medications, which are derived from living organisms and
used to treat complex diseases. These drugs have gained traction due to their
ability to offer comparable efficacy, safety, and quality to their reference
biologic products, while also providing cost savings, leading to the growth of United
Kingdom Immunotherapy Market. In the United Kingdom, biosimilar adoption has
been actively encouraged by healthcare authorities, aiming to reduce healthcare
expenditure without compromising patient outcomes. The United Kingdom government
has implemented several initiatives to encourage the use of biosimilar drugs
and boost the immunotherapy market. The National Health Service (NHS) has
played a pivotal role in promoting the adoption of biosimilars by providing
clear guidelines and support for their use in clinical practice. The NHS has
emphasized the importance of biosimilars in improving patient access to
treatment options and optimizing healthcare resources. Also, immunotherapy has
emerged as a promising avenue in the fight against cancer. This innovative
approach leverages the body's immune system to identify and destroy cancer
cells more effectively. It encompasses a range of therapies, including immune
checkpoint inhibitors, adoptive cell therapies, and cancer vaccines. Collaborations between academia, industry,
and healthcare providers have facilitated the expansion of clinical trials and
the development of new immunotherapeutic agents. These collaborations have
accelerated the process of bringing novel treatments to patients, ensuring that
the United Kingdom remains at the forefront of immunotherapy advancements,
hence augmenting the expansion of United Kingdom Immunotherapy Market.
Despite the remarkable progress, the field of immunotherapy
still faces challenges in the UK. One key hurdle is the high cost associated
with these therapies. The expense of development, production, and personalized
treatment regimens has led to concerns regarding equitable access to
immunotherapies which
may hamper the growth of the market in
the forecast period.
Browse
over XX market data Figures spread through XX Pages and an in-depth TOC on
“United Kingdom Immunotherapy Market “.
The
United Kingdom Immunotherapy Market is segmented into Technology Type, Indication Type, End User, Region, and
Competitive Landscape.
Based on Technology Type, the market is divided
into Monoclonal Antibodies, Cytokines & Immunomodulators, Inhibitors and
Others. Monoclonal Antibodies Immunotherapy is expected to witness a rise over
the forecast period. This is attributed to the fact that monoclonal antibodies
are molecules made in a lab that are designed to act as replacement antibodies
and restore, enhance, modify, or mimic the immune system's attack on
undesirable cells, such as cancer cells, which is anticipated to support market
growth in the future.
Based
on Indication Type, the market is divided into Oncology, Autoimmune Disease,
Infectious Diseases and Others. Oncology Immunotherapy is expected to witness a
rise over the forecast period. This is attributed to the rising prevalence of
cancer in the nation.
Based
on End User, the market is divided into Hospitals & Clinics, Ambulatory
Care Centers, Research & Academic Institutions and Others. The Hospitals & Clinics segment
is expected to witness a rise over the forecast period This can be attributed
to the availability of both inpatient and outpatient medication facilities leading
to the growth of United Kingdom Immunotherapy market.
Major
companies operating in United Kingdom Immunotherapy Market are:
- Johnson
& Johnson
- Novartis
AG
- Bayer
AG
- AstraZeneca
- Pfizer
Inc.
- Sanofi
- GlaxoSmithKline
plc
- Amgen,
Inc
- AbbVie,
Inc
- F.
Hoffmann-La Roche Ltd
Download
Free Sample Report
Customers can also request for 10% free
customization on this report.
“The United Kingdom immunotherapy market
is expected to witness significant growth in the upcoming years due to the
growing adoption of immunotherapy among the geriatric population in the nation.
The increasing healthcare investments and government initiatives for research
and innovation will drive the market in the United Kingdom. Additionally,
increasing technological advancements and the rising number of hospitals in the
nation will strengthen the market's growth, which is expected to continue
through 2028," said Mr. Karan Chechi, Research Director with TechSci
Research, a research-based global management consulting firm.
“United
Kingdom Immunotherapy Market By Technology Type (Monoclonal Antibodies,
Cytokines & Immunomodulators, Inhibitors, Others), By Indication Type
(Oncology, Autoimmune Disease, Infectious Diseases, Others), By End User
(Hospitals & Clinics, Ambulatory Care Centers, Research & Academic
Institutions, Others), By Region, Competition Forecast & Opportunities, 2018-2028F,” has
evaluated the future growth potential of United Kingdom Immunotherapy Market and
provides statistics & information on market size, structure, and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in United Kingdom Immunotherapy Market.
Contact
Mr.
Ken Mathews
708
Third Avenue,
Manhattan,
NY,
New
York 10017
Tel:
+1-646-360-1656
Email: [email protected]
Website: www.techsciresearch.com